GABAB receptor: a site of therapeutic benefit
Introduction
Metabotropic receptors provide the site of action for the majority of therapeutic agents currently in clinical use. However, there are many receptors in this class that have yet to be therapeutically exploited, among which is the GABAB receptor. The natural ligand for this receptor is the amino acid γ-amino-butyric acid (GABA), which is well established as the primary inhibitory transmitter acting at ionotropic GABAA receptors. Many centrally acting drugs mediate their effect(s) by facilitation of GABAA receptor mechanisms, including the benzodiazepines. By contrast, only one compound in current clinical use — baclofen (β p-chlorophenyl-GABA; Figure 1) — is known to mediate its effects directly through activation of the GABAB site. However, substances that increase the extracellular levels of GABA might also produce effects on GABAB sites mediated indirectly by endogenous GABA. Baclofen, which is used to reduce the symptoms of spasticity, was introduced into therapeutic use in 1972 [1, 2], well before the existence of GABAB receptors was recognized and, like so many of the older centrally active agents, its introduction into medicine was not accompanied by a defined mechanism of action, although it was designed as a GABA mimetic. Fortunately, it was screened for muscle relaxant activity using an in vivo technique. Had the compound been screened specifically for ionotropic actions by existing in vitro assays, its effects might have been missed.
The structure of the GABAB receptor was fully identified in 1998 [3, 4, 5] when it was shown to exist as a heterodimer with two subunits, GABAB1 and GABAB2, which provide different functions but are mutually dependent (for review, see [6]). The former contains the GABA-binding domain, whereas GABAB2 provides the G-protein-coupling mechanism and also incorporates an allosteric modulatory site within its heptahelical structure [7, 8, 9•]. Although different functional isoforms of GABAB1 have been defined, there is, as yet, no unequivocal evidence for distinct GABAB receptor subtypes. The receptors are located in the brain both pre- and post-synaptically where they are coupled to Ca2+ and K+ channels. Therefore, when receptor activation occurs, a variety of effects might be expected to occur as a consequence of inhibition of transmitter release and/or neuronal hyperpolarisation. Having a selective agonist for the receptor, together with information derived from ‘knockout’ mice (Table 1), has provided the basis for much of the speculation about the potential therapeutic benefits of both agonists and antagonists for the GABAB receptor.
A list of the in vitro and in vivo actions of baclofen is shown in Table 2; predominant among these are the muscle relaxant, anti-nociceptive and anti-drug craving effects, as well as the reduction in cognitive behaviour.
Section snippets
Spasticity
The centrally mediated muscle-relaxant properties of baclofen are well established clinically, making it the drug of choice in spasticity associated with cerebral palsy, multiple sclerosis, stiff-man syndrome and tetanus. However, the side effects produced by this drug (Table 2) are frequently not tolerated by patients because of the need to administer high doses of the agonist owing to poor brain penetration. This has been largely overcome by the introduction of intrathecal administration
Pain
An analgesic/antinociceptive action of baclofen administered systemically was first described more than 25 years ago and subsequently confirmed by many different groups; however, rapid tolerance to the effects was also noted. If the drug was given intrathecally to suppress central pain in humans, no tolerance was reported. The mechanism underlying this antinociceptive action within the spinal cord appears to derive from suppression of the release of primary afferent transmitter [12, 13, 14].
Cognition
The ability of baclofen to suppress cognitive behaviour in animals is well documented (e.g. see [20]). In general, the effects of baclofen on cognition are comparable to those produced by the muscarinic antagonist scopolamine; however, GABAB-receptor-mediated cognitive impairment is reversed by GABAB antagonists, whereas that produced by scopolamine is not. Although the effect of baclofen is, of course, of little consequence to clinical medicine, there is the possibility that GABAB receptor
Drug addiction
Adequate therapeutic treatment of dependence on drugs of abuse is still a major clinical target but GABAB receptor activation could offer a suitable approach. Baclofen was first shown in 1997 [24] to reduce the reinforcing effects of cocaine in rats at doses that do not affect locomotion. It soon became clear that other drugs of addiction, including nicotine, morphine-related agents and ethanol, were also sensitive to GABAB receptor agonists, whereas food reinforcement was not affected. Indeed,
Depression and anxiety
A connection between GABAB receptors and the action of antidepressants was first proposed more than 20 years ago by Lloyd et al. [34]. These authors demonstrated that an upregulation in GABAB binding sites occurs in rat frontal cortex after chronic administration of a variety of antidepressant drugs, as well as after electroconvulsive therapy. Even though these findings were disputed [35, 36], there now seems little doubt that GABAB receptor mechanisms can be affected in depression [37].
Absence epilepsy
The occurrence of absence seizures is primarily associated with juveniles and frequently disappears during the late teens; however, it can be retained into later years. The characteristic electroencephalogram activity of a 3 Hz spike and wave that is manifest during an absence attack stems from discharges in the thalamic nuclei. It was thought for many years that the thalamus was the site from which these discharges originate; however, although an intact thalamocortical network is necessary for
Conclusions
The full therapeutic benefits of GABAB receptor ligands have yet to be realised even though the existence of the receptor has been known for over 25 years. So one might ask, why? Is it because of the lack of brain-penetrating selective agonists or the lack of effective antagonists? Perhaps the former is true but surely not the latter, as there are now numerous antagonists with sub-nanomolar affinity. However, the one antagonist currently in clinical trials — CGP 36742 (SGS 742) [22•] — only has
References and recommended reading
Papers of particular interest, published within the annual period of review, have been highlighted as:
• of special interest
•• of outstanding interest
Acknowledgements
Thanks to Dr Stefano Tacconi for preparing Figure 2.
References (48)
- et al.
The heptahelical domain of GABAB2 is activated directly by CGP7930, a positive allosteric modulator of the GABAB receptor
J Biol Chem
(2004) - et al.
Presynaptic regulation of spinal cord tachykinin signaling via GABAB but not GABAA receptor activation
Neuroscience
(2001) - et al.
Activation of muscarinic receptors inhibits spinal dorsal horn projection neurons: role of GABAB receptors
Neuroscience
(2004) - et al.
Interaction between gamma-aminobutyric acid GABAB and cannabinoid CB1 receptors in spinal pain pathways in rat
Eur J Pharmacol
(2005) - Potes CS, Neto FL, Castro-Lopes JM: Administration of baclofen, a GABAB agonist, in the thalamic ventrobasal complex...
- et al.
A new approach to control central deafferentation pain: spinal intrathecal baclofen
Stereotact Funct Neurosurg
(1995) - et al.
GABAB receptor antagonist SGS742 improves spatial memory and reduces protein binding to the cAMP response element (CRE) in the hippocampus
Neuropharmacology
(2005) - et al.
SGS742: The first GABAB receptor antagonist in clinical trials
Biochem Pharmacol
(2004) - et al.
Spinal cord SP release and hyperalgesia in monoarthritic rats: Involvement of the GABAB receptor system
Br J Pharmacol
(1994) - et al.
Chronic nicotine and smoke treatment modulate dopaminergic activities in ventral tegmental area and nucleus accumbens and the gamma-aminobutyric acid type B receptor expression of the rat prefrontal cortex
J Neurosci Res
(2004)
Effects of positive allosteric modulators of the GABAB receptor on cocaine self-administration in rats
Psychopharmacology (Berl)
Panicolytic-like effect induced by the stimulation of GABAA and GABAB receptors in the dorsal periaqueductal grey of rats
Eur J Pharmacol
Evolving concepts on the pathophysiology of absence seizures
Arch Neurol
Pharmacology of absence epilepsy
Trends Pharmacol Sci
Epilepsy, hyperalgesia, impaired memory, and loss of pre- and post-synaptic GABAB responses in mice lacking GABAB1
Neuron
Pharmacological differentiations of muscle relaxants
Synthesis and structure-activity relationship of the gamma-aminobutyric acid derivatives
GABAB receptors function as a heteromeric assembly of the subunits GABABR1 and GABABR2
Nature
GABAB receptor subtypes assemble into functional heteromeric complexes
Nature
Heterodimerization is required for the formation of a functional GABAB receptor
Nature
International Union of Pharmacology. XXXIII. Mammalian γ-aminobutyric acidB receptors: structure and function
Pharmacol Rev
The GABAB2 subunit is essential for G protein coupling of the GABAB receptor heterodimer
J Neurosci
The characterization of GABA binding site in GABABR1 receptor shed some light functioning of the heteromeric GABAB receptor
Eur J Neurosci
Intrathecal baclofen for severe spinal spasticity
N Engl J Med
Cited by (210)
Reducing the harms of alcohol: nutritional interventions and functional alcohol alternatives
2024, International Review of NeurobiologyNicotinic acetylcholine receptors: Therapeutic targets for novel ligands to treat pain and inflammation
2023, Pharmacological ResearchToxin-Induced Seizures <sup>∗</sup>Adapted from “Toxin-Induced Seizures” in Neurologic Clinics, November 2020
2022, Emergency Medicine Clinics of North AmericaCan insects feel pain? A review of the neural and behavioural evidence
2022, Advances in Insect PhysiologyMoving from cells to animals: Challenges of studying allosteric modulators in vivo
2022, Allosteric Modulation of G Protein-Coupled Receptors